"Benzimidazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds with a BENZENE fused to IMIDAZOLES.
Descriptor ID |
D001562
|
MeSH Number(s) |
D03.633.100.103
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Benzimidazoles".
Below are MeSH descriptors whose meaning is more specific than "Benzimidazoles".
This graph shows the total number of publications written about "Benzimidazoles" by people in this website by year, and whether "Benzimidazoles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 1 | 2 | 3 |
1995 | 1 | 0 | 1 |
1997 | 0 | 3 | 3 |
1998 | 0 | 1 | 1 |
2001 | 1 | 0 | 1 |
2002 | 0 | 1 | 1 |
2003 | 4 | 3 | 7 |
2004 | 2 | 4 | 6 |
2005 | 2 | 4 | 6 |
2006 | 2 | 1 | 3 |
2007 | 3 | 1 | 4 |
2008 | 2 | 3 | 5 |
2009 | 4 | 1 | 5 |
2010 | 3 | 4 | 7 |
2011 | 7 | 8 | 15 |
2012 | 10 | 2 | 12 |
2013 | 4 | 3 | 7 |
2014 | 6 | 8 | 14 |
2015 | 12 | 7 | 19 |
2016 | 8 | 3 | 11 |
2017 | 8 | 3 | 11 |
2018 | 8 | 8 | 16 |
2019 | 11 | 5 | 16 |
2020 | 7 | 8 | 15 |
2021 | 10 | 12 | 22 |
2022 | 3 | 7 | 10 |
2024 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Benzimidazoles" by people in Profiles.
-
Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. J Infect Dis. 2024 Feb 14; 229(2):413-421.
-
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): Final overall survival results from a randomized phase 3 trial. Eur J Cancer. 2024 Mar; 200:113580.
-
A retrospective analysis of the use of candesartan for migraine prevention in adolescents. Headache. 2024 Jan; 64(1):96-97.
-
Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma. Clin Cancer Res. 2022 07 15; 28(14):3002-3010.
-
Clinical impact of selumetinib on pediatric elephantiasis neuromatosa. Pediatr Dermatol. 2022 Sep; 39(5):764-766.
-
Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC. ESMO Open. 2022 06; 7(3):100477.
-
A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer. Cancer Chemother Pharmacol. 2022 05; 89(5):721-735.
-
Adjuvant Abemaciclib Plus Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A. JCO Oncol Pract. 2022 07; 18(7):516-519.
-
Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial. J Clin Oncol. 2022 07 10; 40(20):2235-2245.
-
Identification of the Benzoimidazole Compound as a Selective FLT3 Inhibitor by Cell-Based High-Throughput Screening of a Diversity Library. J Med Chem. 2022 02 24; 65(4):3597-3605.